Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083   31/12/2025
42,28 USD (+0,91%)
(+0,91%)   31/12/2025
Grafiek Nektar Therapeutics Grafiek Nektar Therapeutics

Nektar Therapeutics in het nieuws

16 december 2025 · REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata · Persbericht

16 december 2025 · Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 · Persbericht

6 december 2025 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

8 november 2025 · New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting · Persbericht

6 november 2025 · Nektar Therapeutics Reports Third Quarter 2025 Financial Results · Persbericht

30 oktober 2025 · Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London · Persbericht

28 oktober 2025 · Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets · Persbericht

22 oktober 2025 · Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting · Persbericht

18 september 2025 · Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 · Persbericht

9 september 2025 · Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 · Persbericht

Profiel Nektar Therapeutics

Biotechnologie
Fabricage van farmaceutische preparaten
Farmaceutica
Gezondheidstechnologie
Productie

Website: www.nektar.com

Hoofdzetel: San Francisco, California vlag Verenigde Staten

Mijn selecties